ProMetic Completes Milestone in Tech Transfer to Sinopharm

ProMetic Life Sciences has completed the first milestone in its strategic collaboration with the Wuhan Institute of Biological Products (WIBP), a subsidiary of China National Pharmaceutical Group Corp (Sinopharm). ProMetic has licensed its proprietary protein technologies to Sinopharm, with the goal of allowing WIBP to produce biosimilar drug products. More details... Stock Symbol: (TSX: PLI)